Nature Search

A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity

Characterisation of monoclonal antibodies against SARS-CoV-2 are useful for potential therapeutics or to understand more about the immune response to this virus. Here the authors characterise a monoclonal antibody that has a broad range of reactivity against SARS-CoV-2 variants and measure how it binds to its specific target region of the receptor binding domain.

Leire de Campos-Mata
Benjamin Trinité
Giuliana Magri
ResearchOpen Access05 Feb 2024
Nature Communications

Volume: 15, P: 1-13
Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses

Long-term characterisation of SARS-CoV-2 antibody kinetics is needed to understand the protective role of the immune response. Here the authors describe antibody levels and neutralisation activity in healthcare workers over seven months and investigate the role of immunity to endemic human coronaviruses.

Natalia Ortega
Marta Ribes
Carlota Dobaño
ResearchOpen Access06 Aug 2021
Nature Communications

Volume: 12, P: 1-10
Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection

In this study, the authors report a mutation that increases the production of recombinant SARS-CoV-2 Spike and exposure of the RBD. In animal models, a Spike-based vaccine containing the mutation induces strong immunogenicity, provides protection from disease and results in faster tissue viral clearance.

Carlos Ávila-Nieto
Júlia Vergara-Alert
Jorge Carrillo
ResearchOpen Access21 Mar 2024
Nature Communications

Volume: 15, P: 1-18
Determinants of antibody levels and protection against omicron BQ.1/XBB breakthrough infection

Pérez et al. evaluate whether antibody levels and neutralization titers correlate with protection against SARS-CoV-2, including Omicron sub-variants BQ.1 and XBB, in a cohort of Spanish healthcare workers. They find an association that wanes over time, highlighting the need for updated vaccination strategies.

Carla Martín Pérez
Anna Ramírez-Morros
Carlota Dobaño
ResearchOpen Access20 Jun 2025
Communications Medicine

Volume: 5, P: 1-13
Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients

Clinical studies have suggested that the therapeutic potential of polyclonal convalescent plasma is highest in the first days of symptoms. Here, the authors present results from a pooled analysis of two clinical trials in COVID-19 outpatients that did not provide conclusive evidence in favor of convalescent plasma.

Pere Millat-Martinez
Arvind Gharbharan
Michael Marks
ResearchOpen Access11 May 2022
Nature Communications

Volume: 13, P: 1-9
Immunisation efficacy of a stabilised SARS-CoV-2 spike glycoprotein in two geriatric animal models

Carla Usai
Erola Ainsua-Enrich
Joaquim Segalés
ResearchOpen Access27 Feb 2024
npj Vaccines

Volume: 9, P: 1-12
An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses

Ferran Tarrés-Freixas
Carmen Aguilar-Gurrieri
Julià Blanco
ResearchOpen Access06 Apr 2023
npj Vaccines

Volume: 8, P: 1-13
Author Correction: Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients

Pere Millat-Martinez
Arvind Gharbharan
Michael Marks
Amendments and CorrectionsOpen Access22 May 2024
Nature Communications

Volume: 15, P: 1
Glucocorticoids’ treatment impairs the medium-term immunogenic response to SARS-CoV-2 mRNA vaccines in Systemic Lupus Erythematosus patients

Silvia Garcia-Cirera
Joan Calvet
Jordi Gratacós
ResearchOpen Access30 Aug 2022
Scientific Reports

Volume: 12, P: 1-9
SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity

Benjamin Trinité
Ferran Tarrés-Freixas
Julià Blanco
ResearchOpen Access28 Jan 2021
Scientific Reports

Volume: 11, P: 1-10
Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2

Lorna Leal
Judit Pich
Elia Torroella
ResearchOpen Access29 Sept 2023
npj Vaccines

Volume: 8, P: 1-12
Author Correction to: SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells

Daniel Perez-Zsolt
Jordana Muñoz-Basagoiti
Nuria Izquierdo-Useros
Amendments and CorrectionsOpen Access11 Jul 2022
Cellular & Molecular Immunology

Volume: 19, P: 965-966
SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells

Daniel Perez-Zsolt
Jordana Muñoz-Basagoiti
Nuria Izquierdo-Useros
CorrespondenceOpen Access15 Nov 2021
Cellular & Molecular Immunology

Volume: 18, P: 2676-2678

Search

A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity

Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses

Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection

Determinants of antibody levels and protection against omicron BQ.1/XBB breakthrough infection

Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients

Immunisation efficacy of a stabilised SARS-CoV-2 spike glycoprotein in two geriatric animal models

An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses

Author Correction: Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients

Glucocorticoids’ treatment impairs the medium-term immunogenic response to SARS-CoV-2 mRNA vaccines in Systemic Lupus Erythematosus patients

SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity

Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2

Author Correction to: SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells

SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells

Search

Quick links

Search

Filter By:

Search

Quick links